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Dendritic cells (DC) are antigen-presenting cells that play a pivotal role in regulating innate
and adaptive immune responses. In autoimmunity, DC act as a double-edged sword since
on one hand they initiate adaptive self-reactive responses and on the other they play a
pivotal role in promoting and maintaining tolerance. Thus, DC are the most important
cells in either triggering self-speciﬁc responses or in negatively regulating auto-reactive
responses.The latter function is mediated by DC in the steady-state or specialized subsets
of DC, named tolerogenic DC. Clinical and experimental evidence indicate that prolonged
presentation of self-antigens by DC is crucial for the development of destructive autoim-
mune diseases, and defects in tolerogenic DC functions contribute to eradication of
self-tolerance. In recent years, DC have emerged as therapeutic targets for limiting their
immunogenicity against self-antigens, while tolerogenic DC have been conceived as ther-
apeutic tools to restore tolerance. The purpose of this review is to give a general overview
of the current knowledge on the pathogenic role of DC in patients affected by autoimmune
diseases. In addition, the protective role of tolerogenic DC will be addressed.The currently
applied strategies to block immune activation or to exploit the tolerogenic potential of DC
will be discussed.
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INTRODUCTION
Dendritic cells (DC) are professional antigen-presenting cells
(APC) specialized in capturing and processing antigens (Ags) to
present to T cells. DC constitute a front-line defense against patho-
gens, are located throughout the body, and formcomplexnetworks
that allow them to communicate with different cells. Therefore,
DC are critically involved in the initiation of adaptive immune
responses and, as such, are deﬁned immunogenic DC. These DC
might be implicated in the induction of autoimmune responses
via the activation of auto-reactive T cells and the consequent
eradication of self-tolerance. Conversely, DC in the steady-state,
or specialized subsets of DC, termed tolerogenic DC, promote
and maintain tolerance through several non-overlapping mech-
anisms. Tolerogenic DC can induce apoptosis of effector T cells,
skew T cell phenotype, and promote anergy and/or regulatory T
cells (Tregs; Morelli and Thomson, 2007; Gregori, 2011). Thus,
defects in the activities of tolerogenic DC may also contribute to
break self-tolerance and to induce autoimmune responses.
An optimal balance between immunogenic and tolerogenic
DC is therefore fundamental to prevent self-reactive immune
responses and to maintain immune self-speciﬁc homeostasis. In
this review, we will give an overview of the different role of both
immunogenic and tolerogenic DC in promoting autoimmune
disease onset and/or progression, focusing primarily on human
pathological conditions.
HUMAN DENDRITIC CELL SUBSETS
Dendritic cells are present in all tissues and they function as
an important bridge between innate and adaptive immunity, by
cellular interactions or through secretion of pro-inﬂammatory
and immuno-regulatory cytokines (Banchereau and Steinman,
1998; Larregina and Falo, 2005; Merad et al., 2008; Rescigno
and Di Sabatino, 2009; Lambrecht and Hammad, 2010;
Thomson, 2010).
In the bloodstream, DC circulate as immature cells charac-
terized by a low expression of human leukocyte antigen (HLA)
class II and co-stimulatory molecules, high endocytic activity, and
low T cell activation potential. Circulating DC constantly patrol
the surrounding environment for pathogens, such as viruses and
bacteria. Upon Ag encounter, DC undergo a complex process of
maturation meanwhile they travel to the lymph nodes, where they
activate helper and cytotoxic T cells as well as B cells. Imma-
ture DC in the steady-state migrate at low ratio to the lymph
nodes without undergoing activation, can present Ags to T cells
in the absence of co-stimulation and induce clonal T cell anergy
(Schwartz et al., 1989), deletion of auto-reactive T cells (Hawiger
et al., 2001; Steinman and Nussenzweig, 2002), and promote Tregs
(Dhodapkar et al., 2001). Tolerogenic DC, both circulating and
tissue resident, contribute to the induction and maintenance of
self-speciﬁc tolerance.
In humans, two major and intrinsically different subpopula-
tions of DC have been described: myeloid DC (myDC), called also
conventional DC, and plasmacytoid DC (pDC), which differ in
their transcriptional program, development, phenotypic markers,
and immunological functions (Belz and Nutt, 2012). myDC pick
upAgs in the periphery andmove to T cell areas of peripheral lym-
phoid organs to initiate immunity through a number of different
events including maturation and cytokine secretion, all of which
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are regulated by recognition of pathogens via Toll-like receptors
(TLR;Watts et al., 2010).
Myeloid DC are present in the peripheral blood and in several
tissues where they acquire specialized functions. In the blood-
stream, several subpopulations of immunogenic myDC, all of
them expressing CD11c, and the myeloid markers CD13 and
CD33, are present (Table 1). These cells include CD16+ (they
are also characterized by the expression of M-DC8; Schakel et al.,
1999), BDCA-1+, and BDCA-3+ (Dzionek et al., 2001) that have
different ability to stimulate allogeneic T cells (MacDonald et al.,
2002). Distinct phenotypical and functional characteristics are dis-
played bymyDC resident in peripheral tissues. ThesemyDCcan be
distinguished according to the expression of speciﬁc markers: lan-
gerin (CD207) expressing cells (Geissmann et al., 2002; Larregina
and Falo, 2005) are Langerhans cells (LC) and interstitial dermal
DC localized in the skin; CD103+ DC reside in the lamina propria
(LP) of the small intestine (Jaensson et al., 2008; Rescigno and Di
Sabatino, 2009); C-type lectin+ (DC-SIGN) DC are present in the
decidua (Laskarin et al., 2007); BDCA-1+ and BDCA-3+ DC have
been described in the lung (Demedts et al., 2005; Table 1).
In addition to immunogenic myDC, other subsets of myDC
with tolerogenic properties have been described such as DC
expressing the scavenger receptor CD163 and immunoglobulin-
like transcript 3 (ILT3; Maniecki et al., 2006). We recently
identiﬁed DC-10, which are tolerogenic DC characterized by the
expression of CD11c+, CD14+, CD16+, CD83+, and the tolero-
genic molecules HLA-G and ILT4 (Gregori et al., 2010). DC-10
display a mature phenotype since they express both HLA class
II and co-stimulatory molecules. They have a unique cytokine
secretion proﬁle consisting of high levels of IL-10 in the absence
of IL-12 (Gregori et al., 2010). Specialized subsets of tolerogenic
DC have been described in each tissue where they maintain tissue
homeostasis and tolerance (reviewed in Gregori, 2011).
Plasmacytoid DC are component of the innate immune system
and are specialized in producing interferon-α (IFN-α) upon acti-
vation via TLR7- and TLR9-mediated recognition of nucleic acids,
and participate in T cell immunity (reviewed by Colonna et al.,
2004). Similar to myDC, immature pDC as well as alternatively
activated pDC are involved in promoting tolerance (Hanabuchi
et al., 2010; Martin-Gayo et al., 2010). pDC are characterized by
the expression of BDCA-2, BDCA-4 (Dzionek et al., 2001), IL-3R
(CD123; Jahnsen et al., 2000), and ILT7 (Cao and Bover, 2010).
pDC are found in the peripheral blood, lymph nodes, and the
thymus, and they are recruited to sites of inﬂammation under
pathological conditions (Swiecki and Colonna, 2010).
DENDRITIC CELLS IN CENTRAL AND PERIPHERAL
TOLERANCE
To avoid autoimmune reactions, self-reactive lymphocytes have to
be deleted or rendered tolerant. Several mechanisms are operating
in the central and peripheral compartments to induce and main-
tain tolerance. Defects in thesemechanisms are associatedwith the
activation of immune responses against self-Ags (Goodnow et al.,
2005). Central tolerance occurs in the thymus and leads to the
deletion of self-reactive T cells through the positive and negative
selection (Hogquist et al., 2005). The role of DC in central toler-
ance has become evident in the last decades. Thymic myDC are
very efﬁcient in mediating negative selection of developing thy-
mocytes (Brocker et al., 1997; Ohnmacht et al., 2009). In addition,
peripheral myDC can migrate to the thymus and contribute to
negative selection (Bonasio et al., 2006; Proietto et al., 2008). Both
thymicmyDC and pDCplay an important role in promoting posi-
tive selection of Tregs (Proietto et al., 2008; Hanabuchi et al., 2010;
Martin-Gayo et al., 2010). Thus, myDC and pDC cooperate in the
thymus to promote on one hand negative selection of self-reactive
T cells, and on the other positive selection of Tregs.
To control immune responses to self-Ags that are not expressed
in the thymus or may escape negative selection, different mech-
anisms of tolerance are operational in the periphery during the
entire lifespan. Mechanisms of peripheral tolerance include cell
death with consequent clonal deletion, development of a state
of T cell unresponsiveness, and active suppression mediated
by Tregs. DC, via the production of the immuno-modulatory
cytokines IL-10 and TGF-β or the expression of the tolerogenic
Table 1 | Different subsets of human dendritic cells.
Tissue distribution Markers Reference
Myeloid DC Immunogenic
BDCA-1 Blood/tissues CD11c, BDCA-1 MacDonald et al. (2002), Dzionek et al. (2000, 2001)
BDCA-3 Blood/tissues CD11c, BDCA-3 MacDonald et al. (2002), Dzionek et al. (2000, 2001)
M-DC8 Blood/tissues M-DC8, CD16 Schakel et al. (1999)
DC-SIGN Blood/decidua CD11c, DC-SIGN Laskarin et al. (2007)
Langerhans cells Skin CD207, CD1a Larregina and Falo (2005), Geissmann et al. (2002)
Myeloid DC tolerogenic
CD163 Blood CD11c, ILT3 Maniecki et al. (2006)
DC-10 Blood/tissues CD11c, CD14, CD16, CD83, HLA-G, ILT4 Gregori et al. (2010)
CD103 Lamina propria CD11c, CD103 Jaensson et al. (2008), Rescigno and Di Sabatino (2009)
Plasmacytoid DC
pDC Blood/tissues BDCA-2, BDCA-4, CD123, ILT7 Dzionek et al. (2000, 2001), Jahnsen et al. (2000), Cao and Bover (2010)
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molecules indoleamine 2,3-dioxygenase (IDO) or ILTs (Morelli
and Thomson, 2007; Gregori, 2011), can regulate several of these
processes.
ROLE OF DENDRITIC CELLS IN PRIMING AND SUSTAINING
SELF-REACTIVE IMMUNE RESPONSES
In genetically susceptible individuals, autoimmune diseases may
develop as a result of alterations in the expression of self-Ags by
DC, or access to immune privileged sites, or modiﬁcation of the
activation state of DC that became potent activators/inducers of
self-reactive effector T cells. Multiple evidences from pre-clinical
models of autoimmune diseases indicate that DC loaded with
self-Ags acquired an activated phenotype and are able to trig-
ger autoimmune responses via the induction of T helper 1 (Th1)
and Th17 responses (Torres-Aguilar et al., 2010). Priming of self-
reactive T cells by activated DC that have taken up apoptotic cell
debris may also lead to break-down self-tolerance and can result
in autoimmunity (Lleo et al., 2008). The pro-inﬂammatory envi-
ronment generally observed in organs target of autoimmunity
can modify several tolerogenic DC functions, shifts the balance
between tolerogenic and immunogenic DC toward the latter, and
contributes to the development of autoimmune diseases.
Several factors in autoimmune patients indicate that the dys-
regulation in the immunogenic and tolerogenic DC is associated
with excessive self-reactive responses and inﬂammation.
ABERRANT ACTIVATION OF IMMUNOGENIC DENDRITIC CELLS
IN HUMAN AUTOIMMUNE DISEASES
In the last decades, studies of DC in patients indicate that aberrant
DC activation or functions are associated with different autoim-
mune diseases as including Rheumatoid Arthritis (RA), Multiple
Sclerosis (MS), Systemic Lupus Erythematosus (SLE), Psoriasis,
and Inﬂammatory Bowel Disease (IBD; Table 2).
Rheumatoid Arthritis
In the peripheral blood of RA patients, but also in synovial ﬂuids
and tissues, increased numbers of myDC and pDC are present
(Lebre and Tak, 2009). Studies on myDC from synovial ﬂuid of
RA patients show that these cells display an activated phenotype as
they express high levels of HLA-DR and co-stimulatorymolecules.
Interestingly, myDC in inﬂamed tissues are associated with T cells
in structures similar to germinal centers where they stimulate self-
reactive T cells (Santiago-Schwarz, 2004). These myDC are also
involved in promoting synovial inﬂammation due to their abil-
ity to secrete pro-inﬂammatory cytokines (Jongbloed et al., 2006;
Lebre et al., 2008).
The role of pDC in the RA pathogenesis is dual: on one hand
in synovial tissues pDC via the secretion of type I IFNs contribute
to local inﬂammation, although at lower extend as compared to
myDC (Pettit et al., 2000; Takakubo et al., 2008); on the other
hand, pDC could play a role in activating B cells via the expression
of B cell-activating factor (Lebre et al., 2008), leading to antibody
production, which sustain tissue damage.
Multiple Sclerosis
The active participationof DC in theMSpathology is supported by
their presence and activation in the central nervous system (CNS)
of MS patients (Pashenkov et al., 2002). Increased frequency of
myDC in the CNS at early stages of the disease and their pres-
ence within the demyelinating lesions indicate that myDC play a
role in re-activating T cell responses to myelin upon entry into
the CNS (Wu and Laufer, 2007). In addition to their identiﬁ-
cation in the CNS during the disease, analyses of myDC in the
peripheral blood of MS patients revealed their ability to secrete
pro-inﬂammatory cytokines at higher levels than DC from nor-
mal donors (Karni et al., 2006). These activated myDC, polarize
CD4+ T cells toward IFN-γ-producing effector cells (Karni et al.,
2006;Vaknin-Dembinsky et al., 2006). Thus,myDC inMSpatients
are highly immunogenic and contribute to disease induction and
progression.
The role of pDC in the MS pathogenesis is less clear. No dif-
ferences in the absolute number of pDC have been found in the
peripheral blood of MS patients. However, a reduced stimula-
tory activity of pDC and a limited expression of co-stimulatory
molecules upon in vitro activation were described, suggesting an
impairment in the maturation and an altered regulatory functions
of pDC in MS patients (Stasiolek et al., 2006).
Systemic Lupus Erythematosus
The induction of SLE and disease severity is associated with a
defect in clearance of apoptotic cells by macrophages (Herrmann
et al., 1998). This results in hyper-activation of DC and leads to
the chronic inﬂammation observed in SLE (Seitz andMatsushima,
2010). When apoptotic cells are not rapidly removed, they release
blebs, in which SLE auto-Ags are clustered, and inducematuration
of DC. TheseDC can stimulate the production of IL-2, IFN-γ, and,
in particular, IL-17 by T cells that sustain autoimmune responses
(Fransen et al., 2009). Although myDC are reduced in the periph-
eral blood of SLE patients (Robak et al., 2004; Migita et al., 2005),
they contribute to effector T cell activation because of their acti-
vated phenotype (Ding et al., 2006; Gerl et al., 2010). In line with
this notion, monocytes from SLE patients undergo an accelerated
differentiation in vitro and express high levels of co-stimulatory
molecules (Ding et al., 2006; Gerl et al., 2010).
Plasmacytoid DC are also reduced in the peripheral blood of
SLE patients (Robak et al., 2004;Migita et al., 2005), but they accu-
mulate in inﬂamed skin lesions (Mori et al., 1994) where they
are selectively attracted by ChemR23, the chemokine receptor for
chemerin (Vermi et al., 2005). Moreover, circulating pDC from
SLEpatientsmigrate in response toCCL19 (Gerl et al., 2010). It has
been proposed that the increased responsiveness to CCL19 might
lead to pDC accumulation in T cell area of lymph nodes where
they increase the priming of self-reactive T cells and contribute to
SLE pathogenesis (Gerl et al., 2010).
Psoriasis
In psoriatic lesions, the frequency of myDC is 30-fold increased
with respect to normal skin (Zaba et al., 2007). The large propor-
tion of these cells secretes TNF-α, IL-12, IL-23, and the inducible
nitric oxide synthase (iNOS; Lowes et al., 2005). These cytokines
activate keratinocytes and ﬁbroblasts to secrete pro-inﬂammatory
cytokines (IL-6 and IL-1) that induce effector Th1 and Th17
cells, contributing to dermal inﬂammation and epidermal
hyperplasia characteristic of psoriasis (Zheng et al., 2007;
Pene et al., 2008).
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Table 2 | Role of dendritic cell subsets in human autoimmune diseases.
Disease DC subsets Localization Function Reference
Rheumatoid Arthritis myDC Blood/synovial tissues ↑ Effector T cell priming
↑ Pro-inﬂammatory cytokines
↑ DC activation
Santiago-Schwarz (2004),
Takakubo et al. (2008)
pDC Synovial tissues ↑ IFN-α production
↑ B cell activation
Takakubo et al. (2008),
Lebre et al. (2008)
Multiple Sclerosis myDC Cerebrospinal ﬂuid ↑T cell activation
↑ Pro-inﬂammatory cytokines
Pashenkov et al. (2002),
Wu and Laufer (2007),
Karni et al. (2006)
pDC Blood Impairment in maturation
↓ Ability to prime FOXP3+ Tregs
Stasiolek et al. (2006)
Systemic Lupus Erythematosus myDC Blood ↑ DC activation
↑ Effector Th1/Th17 cell priming
Seitz and Matsushima (2010),
Fransen et al. (2009)
pDC Inﬂamed lesions/LN ↑ Effector T cell priming Robak et al. (2004),
Migita et al. (2005),
Gerl et al. (2010)
Psoriasis myDC Psoriatic lesions ↑ Pro-inﬂammatory cytokine
↑ Effector T cell priming
Lowes et al. (2005),
Zheng et al. (2007)
pDC Psoriatic lesions ↑ IFN-α production Nestle et al. (2005)
Inﬂammatory Bowel Disease myDC Inﬂamed lesions ↑ DC activation
↑ Pro-inﬂammatory cytokines
↑T cell activation
te Velde et al. (2003),
Hart et al. (2005)
pDC Lamina propria ↑ DC activation
↑ IFN-α production
↓TNF-α production
Baumgart et al. (2011)
The frequency of IFN-α-secreting pDC is also increased in
psoriatic lesions and participate to local inﬂammation (Nestle
et al., 2005).
Inﬂammatory Bowel Disease
Several studies in Crohn’s disease (CD) and ulcerative colitis (UC)
patients have demonstrated an abnormal intestinal accumulation
of DC expressing BDCA-1, which contribute to excessive T cell
activation (de Baey et al., 2003; te Velde et al., 2003; Silva et al.,
2004). DC from CD patients have an altered cytokine production
proﬁle since they produce higher levels of IL-12 and IL-6 than DC
from healthy donors (Hart et al., 2005). Thus, myDC accumulate
in the intestine of IBD patients where they activate pathogenic
T cells.
It has been recently reported that pDC might participate to
inﬂammation in the mucosa of CD and UC patients. Indeed high
frequency of pDC was found in inﬂamed mucosa of CD and UC
patients. Studies on pDC from the peripheral blood of ﬂaring CD
and UC patients demonstrated that they express higher levels of
CD40 and CD86, and they secrete higher amounts of TNF-α than
pDC from healthy subjects. However, these pDC were impaired in
their ability to secrete IFN-α (Baumgart et al., 2011). Thus, these
results suggest that aberrant activationof pDCor alteration in their
regulatory functions could play a role in the pathogenesis of IBD.
These examples clearly indicate that hyper-activation of myDC
is one of the key factors in promoting self-reactive T cell immunity.
Moreover, an aberrant pDC distribution and function contribute
to the local inﬂammation in target organs of autoimmunity. In this
scenario, activated DC are recruited to the inﬂamed tissues where
they secrete pro-inﬂammatory cytokines (i.e., IL-1, TNF-α, IFN-
α, and IL-6) or express high levels of co-stimulatory molecules
that induce an immune-stimulatory loop causing re-activation of
self-reactive T cells and recruitment and/or the activation of other
immune cells, including additional DC.
ALTERATION OF TOLEROGENIC DENDRITIC CELL FUNCTIONS
AND AUTOIMMUNITY
In homeostatic and resting conditions (in the absence of inﬂam-
mation) DC preserve an immature or semi-mature phenotype,
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and actively participate in the maintenance of tolerance toward
self-Ags. In these conditions, tissue resident tolerogenic DC
control self-reactive T cell responses by preventing excessive local
inﬂammation and autoimmune-mediated tissue damages. The
presence of high levels of pro-inﬂammatory mediators observed
in chronic inﬂamed tissues decreases the regulatory activity of
tolerogenic DC.
One of the most important features of tolerogenic DC is
their ability to secrete immuno-regulatory cytokines, such as
IL-10 and TGF-β. IL-10 directly suppresses T cell responses by
inhibiting the secretion of IL-2 and IFN-γ (Vieira et al., 1991)
and by preventing T cell proliferation (Taga and Tosato, 1992).
Similarly, TGF-β potently inhibits T cell responses (Gorelik and
Flavell, 2002). IL-10 controls a number of different cells impli-
cated in inﬂammatory responses, including APC (Mosser and
Zhang, 2008). The expression of HLA class II, co-stimulatory
molecules (de Waal Malefyt et al., 1991) and pro-inﬂammatory
cytokines (Fiorentino et al., 1991a,b) is down-regulated by IL-10.
On the other hand, IL-10 up-regulates the expression of tolero-
genic molecules such as ILT3 and ILT4 (as reviewed in Suciu-Foca
et al., 2005), and HLA-G (Moreau et al., 1999) on APC, render-
ing them capable of dampening immune responses and inducing
Tregs (Carosella et al., 2011). In the steady-state, DC secrete high
levels of IL-10, canmodulate the activation of neighboringmyDC,
and promote the de novo induction of tolerogenic DC. In vitro
studies demonstrated that maturation of monocytes derived DC
in the presence of exogenous IL-10 is inhibited, and resulting
DC become able to induce anergic/suppressive T cells (Steinbrink
et al., 1997, 2002). Moreover, differentiation of monocytes derived
DC in the presence of IL-10 results in a population of mature
myDC, called DC-10, which secrete high levels of IL-10 and are
potent inducers of Ag-speciﬁc IL-10-producing type 1 regulatory
(Tr1) cells in vitro (Gregori et al., 2010; Pacciani et al., 2010). In
addition to their ability to secrete high levels of IL-10, DC-10
strongly express ILT4 and HLA-G, which are necessary for efﬁ-
cient Tr1 cell induction. In inﬂamed tissues, high amounts of
pro-inﬂammatory cytokines lead to the down-regulation of IL-10
production that could impair the modulation of already differen-
tiated DC, and the de novo induction of tolerogenic DC, including
DC-10.
It has been reported that mutations in IL-10 or in its receptor
lead to the loss of IL-10 function and cause severe intractable infant
and adult enterocolitis (Glocker et al., 2009, 2010), demonstrat-
ing the critical role of IL-10 in maintaining intestinal tolerance.
More recently, it has been shown that DC generated from periph-
eral monocytes of IBD children carrying a mutation in IL-10R
secrete signiﬁcantly higher amounts of TNF-α, IL-12, and IL-23
than DC from healthy controls (Begue et al., 2011). These data
indicate that impairment in the ability of DC to produce IL-
10 and to respond to it is critically involved in the pathogenesis
of IBD.
In addition to soluble factors, tolerogenic DC can express
immuno-regulatory enzymes such as IDO and heme oxygenase-1
(HO-1), which suppress T cell responses and promote immune
tolerance. IDO inhibits effector T cell proliferation by reducing
tryptophan that is necessary for cell division (Mellor and Munn,
2004). HO-1 is the rate-limiting enzyme in heme catabolism
and it acts as an anti-inﬂammatory molecules, controlling apop-
tosis, T cell proliferation and activation (Otterbein et al., 2000;
Pae et al., 2004). In non-pathological conditions, Foxp3+ Tregs
promote IDOexpression inmyDCthrough the interactionof cyto-
toxic T-lymphocyte antigen 4 (CTLA-4) with CD80 and CD86
(Fallarino et al., 2002, 2003; Grohmann et al., 2002). Resulting
myDC acquire the ability to generate Foxp3+ Tregs (Mellor and
Munn, 2004). During inﬂammation, chronically activated myDC,
although expressinghigh levels of CD80 andCD86, become refrac-
tory to the inhibitory signal induced by Foxp3+ Tregs and unable
to express IDO.
Indoleamine 2,3-dioxygenase can also be expressed by pDC
alternatively activated with anti-CD40L and IL-3 (Martin-Gayo
et al., 2010) or with thymic stromal lymphopoietin (TSLP;
Hanabuchi et al., 2010). These IDO expressing pDC have been
shown to promote the induction of Foxp3+ Tregs. In the synovial
ﬂuid of RA patients, IDO expressing pDC have been identiﬁed
(Takakubo et al., 2008), but their limited number and the presence
of an increased frequency of activatedmyDC impair their ability to
counteract self-reactive effector T cell responses by the induction
of Tregs.
Immune cells and non-immune cells can play an important
role in driving the development of tolerogenic DC. It has been
shown that human intestinal epithelial cells (IECs) through the
secretion of TSLP, TGF-β, and retinoic acid drive the development
of CD103+ tolerogenic DC (Iliev et al., 2009). CD103+ DC pro-
mote the de novo induction of Foxp3+ Tregs and inhibit Th1 and
Th17 responses (Iliev et al., 2009). In CD patients, IECs do not
express TSLP and fail to control DC-mediated pro-inﬂammatory
responses, resulting in abnormal release of IL-12 (Rimoldi et al.,
2005) and reduced ability to induce CD103+ DC (Rescigno and
Di Sabatino, 2009). This perturbation in the cross-talk between
IECs and DC disrupts the intestinal immune-homeostasis and
promotes gut inﬂammation.
In conclusion, chronic inﬂammation and the presence of high
levels of pro-inﬂammatory cytokines in target organs of autoim-
munity and in the periphery alters the regulatory activity of
tolerogenic DC and generate an imbalance between tolerogenic
and immunogenic DC, which sustains constant activation of
self-reactive T cells leading to tissue damage.
STRATEGIES TO PROMOTE TOLERANCE BY
TARGETING DENDRITIC CELLS
Autoimmune diseases are the result of a potent and de-regulated
immuno-responses toward self-Ags mediated by a variety of
immune cells, including B and T lymphocytes, and APC. The
critical role of DC in the initiation and in the progression of
autoimmune diseases indicates that DC targeting therapies could
represent a good alternative to current immuno-modulatory ther-
apies already approved for the treatment of autoimmune diseases.
Two alternatives approaches can be foreseen to modulate DC:
(i) therapies targeting immunogenic DC to lower their activation,
(ii) therapies targeting tolerogenic DC to improve their function
and induction.
Treatment with monoclonal antibodies (mAb) against pro-
inﬂammatory cytokines or their receptors aiming to reduce theDC
immunogenicity are currently under clinical investigation for the
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treatment of autoimmune diseases. Administration of Anakinra, a
recombinant version of IL-1Rα, in combination with methotrex-
ate (MTX), or of Tocilizumab, a humanized mAb that competes
with IL-6 for receptor binding, provided good clinical beneﬁt
in RA patients (Smolen et al., 2008; Niu et al., 2011). Positive
results were obtained also in patients with RA, CD, and psoria-
sis treated with anti-TNF-α mAb (Inﬂiximab; Present et al., 1999;
Cohen et al., 2000; Ricart et al., 2001). Two recent phase II clini-
cal trials, proved the efﬁcacy and safety of a two different mAbs
against IL-17 (Ixekizumab; Leonardi et al., 2012) or its receptor
(Brodalumab; Papp et al., 2012) for the treatment of Psoriasis.
Despite these encouraging results, additional studies are needed
to evaluate the safety of long-term treatment with these mAbs
and to deﬁne the optimal schedule for their efﬁcacy. Notably,
to obtain stable clinical beneﬁt, chronic administration of these
mAbs is required since clinical symptoms return after treatment
withdrawal.
An alternative approach to block DC immuno-stimulatory
activity is the inhibition of co-stimulatory molecules (CD80 and
CD86). In pre-clinicalmodels of autoimmune diseases the efﬁcacy
of CD28/B7 blockade by CTLA-4Ig has been shown (Salomon and
Bluestone, 2001). Interestingly, while the efﬁcacy and tolerabil-
ity of CTLA-4Ig (Abatacept) have been reported across multiple
international, randomized, double blind, placebo control trials
in patients with active RA (Massarotti, 2008), its effect in other
autoimmune diseases, such as Psoriasis and MS, is still not clear
(Sakthivel, 2009) and additional investigations are required.
Results from these clinical trials indicate that therapies with
mAb aim at inhibiting pro-inﬂammatory cytokines or co-
stimulatory signaling pathways are efﬁcacious; however, they
required long-term administration with consequent long-term
detrimental effects for patients.
Another alternative strategy to restore tolerance in autoim-
munity is to improve the induction and function of tolerogenic
DC. The majority of the efforts have been focused on gener-
ating tolerogenic DC in vitro to be subsequently administered
in vivo as cell therapy, rather than in promoting in vivo the expan-
sion of tolerogenic DC. Different immune-modulatory agents
have been used in order to modify the phenotype, cytokine pro-
ﬁles and activity of DC. Encouraging results have been obtained
by treating DC with biological agents such as dexamethasone
(Piemonti et al., 1999) or vitamin D3 (Penna and Adorini, 2000)
or cytokines such as TNF-α (van Duivenvoorde et al., 2004, 2007)
or IL-10 (Steinbrink et al., 1997, 2002; Sato et al., 2003; Gregori
et al., 2010). In pre-clinical models of arthritis (van Duivenvo-
orde et al., 2004, 2007), EAE (Menges et al., 2002), and type 1
diabetes (T1D; Feili-Hariri et al., 2002) the efﬁcacy of in vitro
induced tolerogenic DC-based cell therapy has been demon-
strated. In addition, repetitive injection of immature DC has been
shown to protect mice from collagen-induced arthritis (Charbon-
nier et al., 2006). To date, in the ﬁeld of autoimmune diseases,
no data have been published using immuno-modulatory pDC as
therapeutic tools.
Despite the fact that in vitro generated human tolerogenic DC
have been studied in research settings, the described methods
have not been translated into clinical grade protocols. Recently
a comparative analysis of good manufacturing practice protocols
to generate human tolerogenic DC using IL-10, TGF-β, vitamin
D3, dexamethasone or rapamycin has been performed (Boks et al.,
2012). Results from this study demonstrated that DC activated
in the presence of IL-10 (IL-10 DC) showed the most powerful
tolerogenic characteristics with high IL-10 production and low
T cell activation. Based on these results the authors suggested
that IL-10 DC are the best suitable subset of tolerogenic DC for
tolerance inducing therapies. We developed a protocol to gener-
ate human tolerogenic DC by differentiating monocyte derived
DC in the presence of exogenous IL-10. Resulting cells, called
DC-10, represent a powerful subset of tolerogenic DC. DC-10
are phenotypically and functionally stable and upon activation
they maintain their cytokine production proﬁle (high IL-10/IL-
12 ratio) and their ability to differentiate adaptive Ag-speciﬁc
Tr1 cells (S. Gregori, personal communication). In alternative
to IL-10, a method to generate clinical grade tolerogenic DC
from patients with RA using vitamin D3 and dexamethasone
has been also developed (Harry et al., 2010) and a clinical trial
for treating RA patients will be initiated soon (Moreau et al.,
2009). Results from this ﬁrst proof of principle clinical trial
will provide informations on the safety and efﬁcacy of tolero-
genic DC-based cell therapy to restore tolerance in autoimmune
settings.
CONCLUSIONS AND PERSPECTIVES
Over the past years signiﬁcant progresses have been achieved
in understanding the pathological role of DC in autoimmune
diseases and how tolerogenic DC regulate and maintain tol-
erance toward self-Ags. Although a number of questions still
remain to be addressed, inhibition of the immunogenic branch
of DC function or induction of the tolerogenic one has become
a feasible approach to restore tolerance in autoimmune diseases.
Current approaches based on the administration of mAb against
immunogenic proteins have been successful, however the lack of
information regarding long-term safety and the chronic infusion
limited their broaden application. Alternatively, in vitro differenti-
ated tolerogenicDCare of great potential interest as cell therapy for
there-establishment of immunological tolerance in autoimmune
diseases. Nevertheless, the optimal type of tolerogenic DC still
remains to be deﬁned. It has to be taken into account that tolero-
genic DC should be resistant to maturation either induced by in
vivo transfer or by inﬂammatory mediators. Moreover, the route
and dose of administration as well as the need of in vivo pharma-
cological treatments for maintaining their tolerogenic functions
have to be still determined. Further studies in humanized mouse
model as well as in large animals will elucidate these aspects
and will allow the establishment of protocols with tolerogenic
DC-based cell therapy for clinical application in autoimmune
diseases.
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